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Assessment, Development and Evaluation) Methods: We evaluated the primary 
endpoint of a random sample from efficacy and effectiveness studies included in 
a systematic review on the treatment of rheumatoid arthritis with anti-TNFs. The 
quality assessment was conducted in accordance with the recommendations of the 
GRADE Working Group available at: www.gradeworkinggroup.org/toolbox/index.
htm. It assigns at first high quality for trials and low quality for observational stud-
ies. Results: The assessment of 8 efficacy and 8 effectiveness studies showed 
respectively that the quality of evidence were high in 5 and 0; moderate in 3 and 
2; low in 0 and 2; and very low in 0 and 4. The risk of bias was present in 3 and 5; 
imprecision results in 0 and 5; elevated magnitude of effect in 6 and 4; controlled 
confounding bias in 0 and 3; presence of dose-response gradient in 0 and 1. Indirect 
evidence and inconsistencies were not found in any of the studies. ConClusions: 
The quality of evidence of 3 trials and 4 observational studies were downgraded, while 
2 observational studies had the quality assessment increased.
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What Value Can OPeRatiOnal Feasibility studies bRing tO POst 
MaRketing ObseRVatiOnal studies (PMOs)? exaMPle OF Feasibility 
study PeRFORMed in easteRn euROPe tO assess hePatitis C ViRal 
disease/Patient ManageMent in Real WORld setting
El Kebir S., Bayle D., Gauchoux R.
Mapi, Real World Evidence, Lyon, France
objeCtives: Operational feasibility studies provide a good opportunity to assess 
practicality of large full-scale studies. They are an almost essential pre-requisite and 
should be well designed with clear objectives. Conducting a pilot study can enhance 
the likelihood of success of PMOS and potentially help to avoid serious design flaws. 
The objective of this research is to assess the value of feasibility studies prior to 
PMOS implementation and highlight the importance of local physicians’ feed-
back. Methods: A feasibility study in 6 Eastern European countries was conducted 
via collection of physician surveys to assess local standard of care. The feasibility 
questionnaire was developed to assess operational aspects, such as availability of 
patient population, site experience and time and willingness to participate. The 37 
physicians who received the questionnaire were selected through PubMed; they 
were all experts who have published regarding HCV infection and were provided 
with the protocol synopsis Results: Out of the 37 selected physicians, 18 gastro-
enterologists, hepatologists, and infectious disease specialists in Bulgaria, Croatia, 
The Czech Republic, Hungary, Poland and Romania completed the questionnaire. 
The participating Physicians were working exclusively in public institutions. The 
average number of HCV patients seen by year is 140 and out of them 78 are treated 
by Interferon. They specified that they can enrol 2 eligible patients per month on 
average. They see their patients frequently during treatment initiation (bi-weekly 
or monthly). However, the follow-up varies from one country to another (quarterly 
or semi-annually). Physicians indicated that patient records and data regarding 
blood tests and procedures are accessible for 100% of the cases. Over 60% of the 
sites were familiar with Patient Reported Outcomes. Overall, 12 physicians were 
interested in participating in the Study. ConClusions: The result of this survey 
helped us documenting routine medical practice and confirming the study design 
and methodology to be implemented.
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use OF suRROgate OutCOMes in health teChnOlOgy assessMents 
(htas)
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: This study analyzes how frequently surrogate outcomes are used 
in HTAs and if the validity of these outcomes are discussed and reported within 
the HTAs. A surrogate outcome is defined by the National Institutes of Health as 
a biomarker intended to substitute for a clinical endpoint. A surrogate outcome 
is used when a clinical endpoint of interest is not ideal or does not occur often 
enough to perform meaningful statistical analysis. It is appropriate to use a sur-
rogate outcome only when there is a strong correlation with the clinical endpoint. 
Before using surrogate outcomes researchers should confirm that the surrogate 
outcome is biologically plausible, has a magnitude of association with the clini-
cal endpoint, and reflects changes in the relevant clinical endpoint. Methods: 
Context Matters (CM) analyzed 1,056 HTAs spanning 38 disease conditions. Each 
HTA had a primary outcome that could be classified as either a surrogate outcome 
or a clinical endpoint. Data was analyzed for eight HTA agencies: AHRQ, DERP, 
SMC, HAS, PBAC, NICE, CADTH, and HIS Scotland. For those HTAs using a sur-
rogate outcome as the primary outcome, CM then determined if the HTA agency 
reported the use of the surrogate and/or discussed the surrogate outcome’s valid-
ity. Results: Ninety-one percent of HTAs used a surrogate outcome (966 HTAs), 
but only 11% (109 HTAs) identified it as a surrogate outcome and/or discussed 
its validity. The agencies that discussed the use of the surrogate outcome most 
often were AHRQ, DERP, and HIS Scotland at 48.1%, 28.6%, and 29.0% of the time, 
respectively. ConClusions: Surrogate endpoints are prevalent in HTAs, but the 
agencies rarely discuss the validity of these endpoints. All agencies failed to dis-
cuss the use of the surrogate endpoint in over 50% of their reviews. HTA agencies 
are not following best practice use of surrogate outcomes.
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in EMBASE and MEDLINE, search terms ‚hemophilia B‘ and ‚FIX‘. Inclusion crite-
ria: journal articles (JA), conference abstracts (CA), English language, published 
between January 2009 and March 2013, studies only. Screening of titles, abstracts 
and full texts was performed subsequently. Registered trials (RT) concerning HB 
or FIX were identified in ClinicalTrials.gov. Analysis comprised age group, spon-
sor, research topic, recruitment status, and study design. Results: Screening of 
1,639 hits yielded 31 JA describing 35 studies, and 62 CA. FIX was the topic of 21 
studies (60.0%) and 29 CA (46.8%). A total of 7 studies focused on various aspects 
of HB, 6 on haemophilia studies with separate data on HB. Gene therapy was the 
main focus of 2 JA and 11 CA (17.7%). Screening of 173 hits from ClinicalTrials.gov 
yielded 47 RT, 42 unpublished. Overall 32 unpublished RT (76.2%) concerned FIX, and 
4 (9.5%) gene therapy. Randomized study design was described in one study (2.9%) 
and 4 RT (9.5%), and 3 studies (8.6%) and 7 RT (16.7%) were prospective observa-
tional comparative. ConClusions: Randomized study design or comparator arms 
were uncommon, and payers’ requirements for evidence were not met. Therefore, 
randomization, comparison to standard of care and documentation of outcome 
should be discussed. Development of refined statistical methods and exploitation 
of complementary data like real-life data may help to fill actual evidence gaps in 
rare diseases.
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the ROle OF dsM in the eMa and Fda authORizatiOn PROCess FOR 
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objeCtives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This 
is significant for clinicians, researchers, and developers of psychopharmacologic 
drugs. The previous version of the DSM, the DSM-IV-TR, was published in 2000 and 
the last time the diagnostic criteria were revised was in 1994, when the DSM-IV 
was published. The objective of this review was to determine how much of a role 
DSM has played in the drug approval process in Europe and the US. Methods: For 
drugs authorized since 2000, summaries of product characteristics (SPCs; EMA) and 
approved labels (FDA) were reviewed to determine how frequently the DSM is men-
tioned in the “clinical particulars” or “indications” sections and how frequently DSM 
criteria are mentioned in the clinical trials sections of the SPCs or labels. The review 
focused on schizophrenia and psychotic disorders, mood disorders, and for the 
FDA, attention-deficit/hyperactivity disorder as well. Results: For EMA-authorized 
products, 8 EPARs met the criteria with 10 indications in total. The DSM was never 
mentioned in the indications or posology sections, but in 7 (70%) of the descriptions 
of pharmacodynamic properties (section 5.1), DSM criteria were cited as the study 
inclusion criteria. For FDA-approved products, 17 labels with 22 indications met the 
review criteria. The DSM was mentioned in 10 of the indications sections (45%) and 
DSM criteria were cited as inclusion criteria in 20 instances (91%). ConClusions: 
Regulators in Europe and the US rely heavily on DSM diagnostic criteria, in the 
sense that these often serve as inclusion criteria for pivotal clinical trials. Given 
significant changes to the criteria in many diagnostic categories, regulators and 
sponsors need to familiarize themselves with the document and evaluate their use 
of DSM criteria going forward.
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POdCasts as a leaRning tOOl in a ReseaRCh MethOds COuRse FOR 
PhaRMaCy students
Nguyen T.L., Lovett A.W., Lundquist L.M., Bonner C.L.
Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA
objeCtives: Podcasts (recorded lectures) can be beneficial for all students, particu-
larly English as a second language students who face language barriers when learn-
ing in another language. There is limited study on pharmacy student perceptions 
and podcasts, none from an international perspective. The primary objective was 
to describe pharmacy students’ perceptions on the usefulness of podcasting and a 
secondary objective was to compare perceptions between native versus non-native 
English speakers in a pharmacy research course. Methods: All first year phar-
macy students (n= 157) attending a Research Methods course in 2012 were invited 
to participate in a survey, which utilized a 4-point Likert Scale (1= strongly disagree, 
2= disagree, 3= agree, and 4= strongly agree). Podcasts covered all course topics such 
as Applied Statistics, Odds Ratio and Relative Risk, Case Reports, Observational 
Studies, Randomized Controlled Trials, and Economic Evaluations. Descriptive sta-
tistics and t-tests were utilized to analyze the data in SPSS. The study was approved 
by the Institutional Review Board. Results: A total of 73% of the class completed 
the survey (40.2% Caucasian, 32% Asian and 25% African American). A total of 24.1% 
identified themselves as non-native English speakers, 94.6% lived in the US for 
greater or equal to 5 years and 66.1% communicated in English at home. The major-
ity of students agreed/strongly agreed that podcasts helped them to prepare for 
exams (92.9%), podcasts were a useful learning tool (91.2%), promoted understand-
ing of course material (89.3%), helped with missed concepts (96.4%), and facilitated 
note-taking at their own pace (92.2%) with mean scores 3.34, 3.27, 3.27, 3.48 and 3.48, 
respectively. Results of the t-test revealed that there is no statistically significant 
difference between native versus non-native English speaking students in their 
perceptions of podcast usefulness (p> .05). ConClusions: Podcasts are beneficial to 
a majority of students, despite their language background. Podcasts have the poten-
tial to be a valuable learning tool for students taking a research methods course.
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gRade FOR Quality assessMent OF eFFiCaCy and eFFeCtiVeness 
studies On anti-tnFs tReatMent OF RheuMatOid aRthRitis
Taino B, Nobre M.R.C
INCOR - HCFMUSP, Sao Paulo, Brazil
objeCtives: Assess the quality of evidence on experimental and observational clini-
cal research through the same approach named GRADE (Grading of Recommendations 
